Literature DB >> 26143433

New World and Old World Leishmania Infections: A Practical Review.

Ines Kevric1, Mark A Cappel1, James H Keeling2.   

Abstract

Leishmaniasis is a parasitic infection endemic to more than 90 countries worldwide. As travel to endemic areas increases, dermatologists need to keep this entity in the differential for any chronic skin lesion in persons who may have had a possible exposure for any duration. It can be difficult to diagnose because manifestations are varied and sometimes subclinical. This article discusses the current state of epidemiology, pathogenesis, clinical presentation, diagnosis, and treatment options. A special focus is placed on cutaneous manifestations and their treatment.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Cutaneous leishmaniasis; Leishmania infection; Leishmaniasis; Mucocutaneous leishmaniasis

Mesh:

Substances:

Year:  2015        PMID: 26143433     DOI: 10.1016/j.det.2015.03.018

Source DB:  PubMed          Journal:  Dermatol Clin        ISSN: 0733-8635            Impact factor:   3.478


  57 in total

1.  Multilesional cutaneous leishmaniasis.

Authors:  Yuval Ramot; Abraham Zlotogorski
Journal:  CMAJ       Date:  2016-05-16       Impact factor: 8.262

2.  High levels of serum glycans monovalent IgG immune complexes detected by dissociative ELISA in experimental visceral leishmaniasis.

Authors:  Camila Aparecida de Carvalho; Thiago Fidelis Ferrão; Flávia Regina Novais de Freitas; Heitor Franco de Andrade
Journal:  Immunology       Date:  2019-10-01       Impact factor: 7.397

3.  VOSalophen: a vanadium complex with a stilbene derivative-induction of apoptosis, autophagy, and efficiency in experimental cutaneous leishmaniasis.

Authors:  Patrícia de A Machado; Jessica O F Moraes; Gustavo S G Carvalho; Wallace P Lima; Gilson C Macedo; Elizandra A Britta; Celso V Nakamura; Adilson D da Silva; Alexandre Cuin; Elaine S Coimbra
Journal:  J Biol Inorg Chem       Date:  2017-06-08       Impact factor: 3.358

4.  Susceptibility of promastigotes and intracellular amastigotes from distinct Leishmania species to the calpain inhibitor MDL28170.

Authors:  Pedro Soares de Sousa Araújo; Simone Santiago Carvalho de Oliveira; Claudia Masini d'Avila-Levy; André Luis Souza Dos Santos; Marta Helena Branquinha
Journal:  Parasitol Res       Date:  2018-05-04       Impact factor: 2.289

Review 5.  Leishmania vaccine development: exploiting the host-vector-parasite interface.

Authors:  S G Reed; R N Coler; D Mondal; S Kamhawi; J G Valenzuela
Journal:  Expert Rev Vaccines       Date:  2015-11-23       Impact factor: 5.217

6.  Depot Subcutaneous Injection with Chalcone CH8-Loaded Poly(Lactic-Co-Glycolic Acid) Microspheres as a Single-Dose Treatment of Cutaneous Leishmaniasis.

Authors:  Ariane de Jesus Sousa-Batista; Wallace Pacienza-Lima; Natalia Arruda-Costa; Camila Alves Bandeira Falcão; Maria Ines Ré; Bartira Rossi-Bergmann
Journal:  Antimicrob Agents Chemother       Date:  2018-02-23       Impact factor: 5.191

7.  A New Antileishmanial Preparation of Combined Solamargine and Solasonine Heals Cutaneous Leishmaniasis through Different Immunochemical Pathways.

Authors:  C M Lezama-Dávila; J D McChesney; J K Bastos; M A Miranda; R F Tiossi; J de C da Costa; M V Bentley; S E Gaitan-Puch; A P Isaac-Márquez
Journal:  Antimicrob Agents Chemother       Date:  2016-04-22       Impact factor: 5.191

Review 8.  Leishmania infection: painful or painless?

Authors:  Sergio M Borghi; Victor Fattori; Ivete Conchon-Costa; Phileno Pinge-Filho; Wander R Pavanelli; Waldiceu A Verri
Journal:  Parasitol Res       Date:  2016-12-09       Impact factor: 2.289

9.  Prevalence of and Factors Associated with Negative Microscopic Diagnosis of Cutaneous Leishmaniasis in Rural Peru.

Authors:  Ryan Lamm; Clark Alves; Grace Perrotta; Meagan Murphy; Catherine Messina; Juan F Sanchez; Erika Perez; Luis Angel Rosales; Andres G Lescano; Edward Smith; Hugo Valdivia; Jack Fuhrer; Sarah-Blythe Ballard
Journal:  Am J Trop Med Hyg       Date:  2018-05-31       Impact factor: 2.345

10.  Effectiveness and Safety of Amphotericin B Deoxycholate, Amphotericin B Colloidal Dispersion, and Liposomal Amphotericin B as Third-Line Treatments for Cutaneous and Mucocutaneous Leishmaniasis: A Retrospective Study.

Authors:  María Claudia Rodríguez Galvis; Jairo Enrique Pérez Franco; Mirian Yolanda Casas Vargas; María Fernanda Ordoñez Rubiano
Journal:  Am J Trop Med Hyg       Date:  2020-02       Impact factor: 2.345

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.